Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens
Safeguarding patients from emerging infectious diseases demands strategies that prioritise patient well-being and protection. Immunobridging is an established trial methodology which has been increasingly employed to ensure patient protection and provide clinicians with swift access to vaccines. It...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/1/19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587357399810048 |
|---|---|
| author | Pedro Cruz Jie Min Lam Jehad Abdalla Samira Bell Jola Bytyci Tal Brosh-Nissimov John Gill Ghady Haidar Michael Hoerger Yasmin Maor Antonio Pagliuca Francois Raffi Ffion Samuels Dorry Segev Yuxin Ying Lennard Y. W. Lee |
| author_facet | Pedro Cruz Jie Min Lam Jehad Abdalla Samira Bell Jola Bytyci Tal Brosh-Nissimov John Gill Ghady Haidar Michael Hoerger Yasmin Maor Antonio Pagliuca Francois Raffi Ffion Samuels Dorry Segev Yuxin Ying Lennard Y. W. Lee |
| author_sort | Pedro Cruz |
| collection | DOAJ |
| description | Safeguarding patients from emerging infectious diseases demands strategies that prioritise patient well-being and protection. Immunobridging is an established trial methodology which has been increasingly employed to ensure patient protection and provide clinicians with swift access to vaccines. It uses immunological markers to infer the effectiveness of a new drug through a surrogate measure of efficacy. Recently, this method has also been employed to authorise novel drugs, such as COVID-19 vaccines, and this article explores the concepts behind immunobridging trials, their advantages, issues, and significance in the context of COVID-19 and other infectious diseases. Our goal is to improve awareness among clinicians, patient groups, regulators, and health leaders of the opportunities and issues of immunobridging, so that fewer patients are left without protection from infectious diseases, particularly from major pathogens that may emerge. |
| format | Article |
| id | doaj-art-675b36e693664ce4a788e9ca5dd33db4 |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-675b36e693664ce4a788e9ca5dd33db42025-01-24T13:51:41ZengMDPI AGVaccines2076-393X2024-12-011311910.3390/vaccines13010019Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving PathogensPedro Cruz0Jie Min Lam1Jehad Abdalla2Samira Bell3Jola Bytyci4Tal Brosh-Nissimov5John Gill6Ghady Haidar7Michael Hoerger8Yasmin Maor9Antonio Pagliuca10Francois Raffi11Ffion Samuels12Dorry Segev13Yuxin Ying14Lennard Y. W. Lee15Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto. CCC Raquel Seruca), 4200-072 Porto, PortugalUniversity College London, London WC1E 6BT, UKAl Rahba Hospital, HMCV+XHF, AL Shahama, United Arab EmiratesDivision of Population Health and Genomics, University of Dundee, Dundee DD1 4HN, UKUniversity of Oxford, Oxford OX1 2JD, UKInfectious Diseases Unit, Samson Assuta Ashdod University Hospital, Ashdod 7747629, IsraelDivision of Nephrology, St. Paul’s Hospital, The University of British Columbia, Vancouver, BC V6Z 1Y6, CanadaUniversity of Pittsburgh, Pittsburgh, PA 15260, USATulane University, New Orleans, LA 70118, USAInfectious Disease Unit, Edith Wolfson Medical Center, Holon 5822012, IsraelKings College London, London WC2R 2LS, UKCHU Nantes, INSERM, Department of Infectious Diseases, Nantes Université, CIC 1413, 44093 Nantes, FranceUniversity of Oxford, Oxford OX1 2JD, UKNYU Grossman School of Medicine, New York, NY 10016, USAUniversity of Oxford, Oxford OX1 2JD, UKCentre for Immuno-Oncology, University of Oxford, Oxford OX3 7DQ, UKSafeguarding patients from emerging infectious diseases demands strategies that prioritise patient well-being and protection. Immunobridging is an established trial methodology which has been increasingly employed to ensure patient protection and provide clinicians with swift access to vaccines. It uses immunological markers to infer the effectiveness of a new drug through a surrogate measure of efficacy. Recently, this method has also been employed to authorise novel drugs, such as COVID-19 vaccines, and this article explores the concepts behind immunobridging trials, their advantages, issues, and significance in the context of COVID-19 and other infectious diseases. Our goal is to improve awareness among clinicians, patient groups, regulators, and health leaders of the opportunities and issues of immunobridging, so that fewer patients are left without protection from infectious diseases, particularly from major pathogens that may emerge.https://www.mdpi.com/2076-393X/13/1/19immunobridgingclinical trialsimmunocompromisevaccinesmonoclonal antibodies |
| spellingShingle | Pedro Cruz Jie Min Lam Jehad Abdalla Samira Bell Jola Bytyci Tal Brosh-Nissimov John Gill Ghady Haidar Michael Hoerger Yasmin Maor Antonio Pagliuca Francois Raffi Ffion Samuels Dorry Segev Yuxin Ying Lennard Y. W. Lee Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens Vaccines immunobridging clinical trials immunocompromise vaccines monoclonal antibodies |
| title | Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens |
| title_full | Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens |
| title_fullStr | Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens |
| title_full_unstemmed | Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens |
| title_short | Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens |
| title_sort | immunobridging trials an important tool to protect vulnerable and immunocompromised patients against evolving pathogens |
| topic | immunobridging clinical trials immunocompromise vaccines monoclonal antibodies |
| url | https://www.mdpi.com/2076-393X/13/1/19 |
| work_keys_str_mv | AT pedrocruz immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT jieminlam immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT jehadabdalla immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT samirabell immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT jolabytyci immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT talbroshnissimov immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT johngill immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT ghadyhaidar immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT michaelhoerger immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT yasminmaor immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT antoniopagliuca immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT francoisraffi immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT ffionsamuels immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT dorrysegev immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT yuxinying immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens AT lennardywlee immunobridgingtrialsanimportanttooltoprotectvulnerableandimmunocompromisedpatientsagainstevolvingpathogens |